Ronald Herbst follows MedImmune exodus to Pyxis CSO post; Jeff Goddard to succeed CEO of AIT Bioscience
→ The outflow of top execs from MedImmune continues to fill the leadership ranks of smaller biotechs. The latest to take off is Ronald Herbst, the head of oncology research, who’s assuming the CSO post at Pyxis Oncology.
Herbst was part of the old MedImmune organization AstraZeneca CEO Pascal Soriot restructured earlier this year, reorganizing the company and eliminating the storied subsidiary as a separate organization.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.